



Clinical trial results:

A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Summary

EudraCT number	2019-004630-42
Trial protocol	FR PT DE PL IT
Global end of trial date	22 April 2024

Results information

Result version number	v1
This version publication date	31 January 2025
First version publication date	31 January 2025

Trial information

Trial identification

Sponsor protocol code	TAS-120-301
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04093362
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Taiho Oncology, Inc.
Sponsor organisation address	101 Carnegie Center, Suite 101, Princeton, New Jersey, United States, 08540
Public contact	Senior Study Manager, Taiho Oncology, Inc, +1 844-878-2446, medicalinformation@taihooncology.com
Scientific contact	Senior Study Manager, Taiho Oncology, Inc, +1 844-878-2446, medicalinformation@taihooncology.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	28 April 2023
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	22 April 2024
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The main objective of the trial was to evaluate the efficacy and safety of futibatinib versus gemcitabine-cisplatin chemotherapy as first-line treatment of subjects with advanced, metastatic, or recurrent unresectable intrahepatic cholangiocarcinoma (iCCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements.

Protection of trial subjects:

All study subjects were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 January 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 1
Country: Number of subjects enrolled	France: 1
Country: Number of subjects enrolled	Brazil: 4
Country: Number of subjects enrolled	Taiwan: 1
Country: Number of subjects enrolled	Korea, Republic of: 1
Country: Number of subjects enrolled	United States: 2
Worldwide total number of subjects	10
EEA total number of subjects	2

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	5
From 65 to 84 years	5
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

A total of 10 subjects took part in the study from 06 January 2021 to 22 April 2023.

Pre-assignment

Screening details:

Total 10 subjects with advanced cholangiocarcinoma were enrolled & randomised to receive either futibatinib or gemcitabine-cisplatin. The study was later terminated by the sponsor due to poor recruitment.

Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Futibatinib

Arm description:

Subjects received futibatinib at an oral dose of 20 milligrams (mg), administered once daily (QD) in each 21-day cycle up to a maximum of 649 days.

Arm type	Experimental
Investigational medicinal product name	Futibatinib
Investigational medicinal product code	
Other name	TAS-120
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Futibatinib at an oral dose of 20 milligrams (mg), administered daily (QD) on every day of a 21-day cycle.

Arm title	Gemcitabine-Cisplatin
------------------	-----------------------

Arm description:

Subjects received cisplatin 25 milligrams per square meter (mg/m²) intravenous (IV) infusion followed by gemcitabine 1000 mg/m² IV infusion on Days 1 and 8 of each 21-day cycle up to a maximum of 155 days.

Arm type	Experimental
Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Cisplatin 25 mg/m², IV infusion on Days 1 and 8 of each 21-day cycle.

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Gemcitabine 1000 mg/m², IV infusion on Days 1 and 8 of each 21-day cycle.

Number of subjects in period 1	Futibatinib	Gemcitabine- Cisplatin
Started	4	6
Completed	0	0
Not completed	4	6
Withdrawal of Consent	1	-
Study Termination	1	1
Death	1	3
Reason not Specified	1	2

Baseline characteristics

Reporting groups

Reporting group title	Futibatinib
Reporting group description:	
Subjects received futibatinib at an oral dose of 20 milligrams (mg), administered once daily (QD) in each 21-day cycle up to a maximum of 649 days.	
Reporting group title	Gemcitabine-Cisplatin
Reporting group description:	
Subjects received cisplatin 25 milligrams per square meter (mg/m ²) intravenous (IV) infusion followed by gemcitabine 1000 mg/m ² IV infusion on Days 1 and 8 of each 21-day cycle up to a maximum of 155 days.	

Reporting group values	Futibatinib	Gemcitabine-Cisplatin	Total
Number of subjects	4	6	10
Age categorical Units: Subjects			
Age continuous Units: years			
arithmetic mean	69.3	56.3	
standard deviation	± 9.46	± 12.77	-
Gender categorical Units: Subjects			
Female	1	4	5
Male	3	2	5
Ethnicity Units: Subjects			
Hispanic or Latino	1	3	4
Not Hispanic or Latino	3	2	5
Unknown or Not Reported	0	1	1
Race Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	2	0	2
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	2	5	7
More than one race	0	0	0
Unknown or Not Reported	0	1	1

End points

End points reporting groups

Reporting group title	Futibatinib
Reporting group description:	
Subjects received futibatinib at an oral dose of 20 milligrams (mg), administered once daily (QD) in each 21-day cycle up to a maximum of 649 days.	
Reporting group title	Gemcitabine-Cisplatin
Reporting group description:	
Subjects received cisplatin 25 milligrams per square meter (mg/m ²) intravenous (IV) infusion followed by gemcitabine 1000 mg/m ² IV infusion on Days 1 and 8 of each 21-day cycle up to a maximum of 155 days.	

Primary: Progression-free Survival (PFS)

End point title	Progression-free Survival (PFS) ^[1]
End point description:	
PFS was defined as the time from date of randomization to the date of documentation of disease progression by independent central review (ICR), or date of death, whichever occurs first. Response assessments were made based on Response Evaluation Criteria in Solid Tumours (RECIST) guidelines (version 1.1, 2009). As pre-specified in protocol, a total of 162 PFS events were required to perform PFS analysis. As only 10 subjects were enrolled in this study, hence no data was collected or analysed as planned for this end point.	
End point type	Primary
End point timeframe:	
Up to approximately 28 months	
Notes:	
[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: As pre-specified in protocol, a total of 162 PFS events were required to perform PFS analysis. As only 10 subjects were enrolled in this study, hence no data was collected or analysed as planned for this end point.	

End point values	Futibatinib	Gemcitabine-Cisplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[2]	0 ^[3]		
Units: Subjects				

Notes:	
[2] - Only 10 subjects were enrolled in this study, no data was collected or analysed as planned.	
[3] - Only 10 subjects were enrolled in this study, no data was collected or analysed as planned.	

Statistical analyses

No statistical analyses for this end point

Secondary: Objective Response Rate (ORR)

End point title	Objective Response Rate (ORR)
End point description:	
ORR was defined as the proportion of subjects experiencing a best overall response of partial response (PR) or complete response (CR) as per RECIST 1.1, based on ICR. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters and persistence of one or more non-target lesion(s) and/or maintenance of tumour marker level above the normal limits. CR was defined as disappearance of all target lesions. Any pathological lymph node	

must have reduction in short axis to less than (<)10 millimeters (mm) and disappearance of all non-target lesions and normalisation of tumour marker level. All lymph nodes must be non-pathological in size (<10-mm short axis). The data for this end point was not collected or analysed as planned because the study was terminated early due to poor recruitment.

End point type	Secondary
End point timeframe:	
Up to approximately 28 months	

End point values	Futibatinib	Gemcitabine-Cisplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[4]	0 ^[5]		
Units: Subjects				

Notes:

[4] - The data for this end point was not collected as planned due to poor recruitment.

[5] - The data for this end point was not collected as planned due to poor recruitment.

Statistical analyses

No statistical analyses for this end point

Secondary: Disease Control Rate (DCR)

End point title	Disease Control Rate (DCR)
End point description:	
DCR was defined as the proportion of subjects experiencing a best overall response of stable disease (SD), PR or CR as per RECIST 1.1, based on central assessment of radiologic images. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters and persistence of one or more non-target lesion(s) and/or maintenance of tumour marker level above the normal limits. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to <10 mm and disappearance of all non-target lesions and normalisation of tumour marker level. All lymph nodes must be non-pathological in size (<10-mm short axis). The data for this end point was not collected or analysed as planned because the study was terminated early due to poor recruitment.	
End point type	Secondary
End point timeframe:	
Up to approximately 28 months	

End point values	Futibatinib	Gemcitabine-Cisplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[6]	0 ^[7]		
Units: Subjects				

Notes:

[6] - The data for this end point was not collected due to poor recruitment.

[7] - The data for this end point was not collected due to poor recruitment.

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
-----------------	-----------------------

End point description:

OS was defined as the time from the date of randomisation until the date of death due to any cause. All Treated Population included all subjects who received at least one dose of study drug. The data for this end point was not collected or analysed as planned because the study was terminated early due to poor recruitment.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 28 months

End point values	Futibatinib	Gemcitabine-Cisplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[8]	0 ^[9]		
Units: months				
median (full range (min-max))	(to)	(to)		

Notes:

[8] - The data for this end point was not collected due to poor recruitment.

[9] - The data for this end point was not collected due to poor recruitment.

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-Free Survival (PFS) Per Investigator Assessment

End point title	Progression-Free Survival (PFS) Per Investigator Assessment
-----------------	---

End point description:

PFS per investigator assessment is defined as the time from date of randomisation to the date of disease progression based on investigator assessment of radiographic images or death, whichever occurs first. As pre-specified in protocol, a total of 162 PFS events were required to perform PFS analysis. As only 10 subjects were enrolled in this study, hence no data was collected for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 28 months

End point values	Futibatinib	Gemcitabine-Cisplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[10]	0 ^[11]		
Units: Subjects				

Notes:

[10] - Only 10 subjects were enrolled in this study, hence no data was collected for this end point.

[11] - Only 10 subjects were enrolled in this study, hence no data was collected for this end point.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Treatment-emergent Adverse Events (TEAEs), and Serious Adverse Events (SAEs)

End point title	Number of Subjects With Treatment-emergent Adverse Events (TEAEs), and Serious Adverse Events (SAEs)
-----------------	--

End point description:

Adverse event (AE): any untoward medical condition in clinical investigation subject administered drug; it does not necessarily have causal relationship with treatment. TEAE: AE that started or worsened at time of/after first dose of study drug administration & within 30 days after last dose of study drug & does not necessarily have a causal relationship to use of study drug. TEAEs were assessed by Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0). SAE: untoward medical occurrence that at any dose: results in death, is life-threatening, required in subject hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is congenital anomaly/birth defect, important medical event. TEAEs included any clinically significant changes in clinical laboratory tests, vital signs, ophthalmological exams & 12-lead electrocardiogram (ECG). All Treated Population included all subjects who received at least one dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 28 months

End point values	Futibatinib	Gemcitabine-Cisplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4	5		
Units: Subjects				
TEAEs	4	5		
SAEs	2	3		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug up to end of study (Up to approximately 28 months)

Adverse event reporting additional description:

All Treated Population included all subjects who received at least one dose of study drug.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	V25.0
--------------------	-------

Reporting groups

Reporting group title	Futibatinib
-----------------------	-------------

Reporting group description: -

Reporting group title	Gemcitabine-Cisplatin
-----------------------	-----------------------

Reporting group description: -

Serious adverse events	Futibatinib	Gemcitabine-Cisplatin	
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 4 (50.00%)	3 / 5 (60.00%)	
number of deaths (all causes)	1	3	
number of deaths resulting from adverse events	1	3	
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
General physical health deterioration			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal varices haemorrhage			

subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abdominal sepsis			
subjects affected / exposed	0 / 4 (0.00%)	2 / 5 (40.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Futibatinib	Gemcitabine-Cisplatin	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 4 (100.00%)	5 / 5 (100.00%)	
Vascular disorders			
Phlebitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	
General disorders and administration site conditions			

Asthenia			
subjects affected / exposed	1 / 4 (25.00%)	1 / 5 (20.00%)	
occurrences (all)	1	1	
Face oedema			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	
occurrences (all)	1	0	
Fatigue			
subjects affected / exposed	1 / 4 (25.00%)	2 / 5 (40.00%)	
occurrences (all)	1	2	
Influenza like illness			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	
occurrences (all)	1	0	
Oedema peripheral			
subjects affected / exposed	0 / 4 (0.00%)	3 / 5 (60.00%)	
occurrences (all)	0	3	
Mucosal inflammation			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	
occurrences (all)	2	0	
Productive cough			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	
occurrences (all)	1	0	
Epistaxis			
subjects affected / exposed	0 / 4 (0.00%)	2 / 5 (40.00%)	
occurrences (all)	0	2	
Hiccups			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	
Oropharyngeal pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	
Pulmonary embolism			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1	
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 5 (20.00%) 1	
Investigations Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0	
Blood bilirubin increased subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 5 (20.00%) 1	
Blood follicle stimulating hormone decreased subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0	
Lipase increased subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 5 (20.00%) 1	
Neutrophil count decreased subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 4	1 / 5 (20.00%) 2	
Platelet count decreased subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 5 (20.00%) 2	
Weight decreased subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0	
Weight increased subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0	
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	2 / 5 (40.00%) 2	
Aspartate aminotransferase increased			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	2 / 5 (40.00%) 2	
International normalised ratio increased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1	
White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 2	
Cardiac disorders Atrioventricular block second degree subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0	
Nervous system disorders Headache subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 2	
Blood and lymphatic system disorders Lymphopenia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 2	0 / 5 (0.00%) 0	
Anaemia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	3 / 5 (60.00%) 3	
Leukopenia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1	
Neutropenia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1	
Thrombocytopenia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1	
Eye disorders Ocular hyperaemia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0	

Serous retinopathy subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0	
Retinal haemorrhage subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1	
Visual impairment subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1	
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	3 / 5 (60.00%) 4	
Diarrhoea subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 2	2 / 5 (40.00%) 2	
Ascites subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	2 / 5 (40.00%) 2	
Stomatitis subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 2	0 / 5 (0.00%) 0	
Nausea subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	5 / 5 (100.00%) 6	
Constipation subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	3 / 5 (60.00%) 5	
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	2 / 5 (40.00%) 2	
Dyspepsia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1	
Gingival bleeding			

subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	
Vomiting			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	
Hepatobiliary disorders			
Jaundice cholestatic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	2 / 4 (50.00%)	0 / 5 (0.00%)	
occurrences (all)	2	0	
Pruritus			
subjects affected / exposed	2 / 4 (50.00%)	0 / 5 (0.00%)	
occurrences (all)	2	0	
Onycholysis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	
occurrences (all)	1	0	
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	
occurrences (all)	1	0	
Night sweats			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	
Petechiae			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	
Renal and urinary disorders			
Urinary retention			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	
occurrences (all)	1	0	
Dysuria			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	
Endocrine disorders			

Adrenal insufficiency subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0	
Musculoskeletal and connective tissue disorders Pain in extremity subjects affected / exposed occurrences (all) Back pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0 0 / 4 (0.00%) 0	2 / 5 (40.00%) 2 1 / 5 (20.00%) 1	
Infections and infestations COVID-19 subjects affected / exposed occurrences (all) Paronychia subjects affected / exposed occurrences (all) Tooth abscess subjects affected / exposed occurrences (all) Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1 1 / 4 (25.00%) 1 1 / 4 (25.00%) 1 0 / 4 (0.00%) 0	0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 1 / 5 (20.00%) 1	
Metabolism and nutrition disorders Hyperphosphataemia subjects affected / exposed occurrences (all) Decreased appetite subjects affected / exposed occurrences (all) Hyperkalaemia subjects affected / exposed occurrences (all) Hypoalbuminaemia subjects affected / exposed occurrences (all)	3 / 4 (75.00%) 12 1 / 4 (25.00%) 2 1 / 4 (25.00%) 2 1 / 4 (25.00%) 1	0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 2 / 5 (40.00%) 2 2 / 5 (40.00%) 3	

Hypochloraemia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	
occurrences (all)	1	0	
Hyponatraemia			
subjects affected / exposed	1 / 4 (25.00%)	1 / 5 (20.00%)	
occurrences (all)	1	1	
Hypomagnesaemia			
subjects affected / exposed	0 / 4 (0.00%)	2 / 5 (40.00%)	
occurrences (all)	0	2	
Vitamin D deficiency			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 January 2020	The following changes were made as per Amendment 1: 1. The EudraCT number on the cover page was corrected. 2. The requirement that phosphorus be assessed on Day 4 of Cycle 1 was removed from Table 1 (Schedule of Events) and throughout the protocol (the schedule for all other chemistry assessments remains the same as in the original version).

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The data for the end points related to PFS, OS, ORR, and DCR per Investigator assessment was not collected or analysed as planned because the study was terminated early due to poor recruitment.

Notes: